Literature DB >> 14605133

Enzyme-linked immunosorbent assay employing a recombinant antigen for detection of protective antibody against swine erysipelas.

Yumiko Imada1, Yasuyuki Mori, Masaji Daizoh, Kazuma Kudoh, Tetsuya Sakano.   

Abstract

The specificities and sensitivities of five recombinant proteins of the surface protective antigen (SpaA) of Erysipelothrix rhusiopathiae were examined by indirect enzyme-linked immunosorbent assay (ELISA) with the aim of developing a reliable serological test for the detection of protective antibody against E. rhusiopathiae. Fully mature protein and the N-terminal 416 amino acids (SpaA416) showed sufficient antigenicities, and further examination was done with SpaA416 because of its higher yield. The antibody titers of pigs experimentally immunized with commercial live vaccine and two types of inactivated vaccines clearly increased after immunization, and all pigs were completely protected against challenge with virulent strains. On the other hand, the antibody titers of nonimmunized control pigs remained very low until they were challenged, and all showed severe symptoms or subsequently died. Interference with the production of antibody against live vaccine by maternal antibody or porcine respiratory and reproductive syndrome virus infection 1 week after vaccination was also clearly detected. Because the ELISA titer correlated well with the protection results, the specificity and sensitivity of the ELISA were further evaluated with sera collected from pigs reared on 1 farm on which animals had acute septicemia, 2 farms on which the animals were infected or free from infection, and 10 farms on which the animals were vaccinated with live vaccine, among others. The ELISA titers clearly revealed the conditions of the herds. These results indicate that the SpaA416 ELISA is an effective method not only for evaluating pigs for the presence of protective antibody levels resulting from vaccination or maternal antibody but also for detecting antibody produced by natural infection. This test has important potential for the effective control of swine erysipelas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605133      PMCID: PMC262546          DOI: 10.1128/JCM.41.11.5015-5021.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  [Subclinical erysipelas and its significance for epidemiology of erysipelas].

Authors:  G WELLMANN
Journal:  Zentralbl Bakteriol Orig       Date:  1955

2.  Truncated surface protective antigen (SpaA) of Erysipelothrix rhusiopathiae serotype 1a elicits protection against challenge with serotypes 1a and 2b in pigs.

Authors:  Y Imada; N Goji; H Ishikawa; M Kishima; T Sekizaki
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Properties of repeat domain found in a novel protective antigen, SpaA, of Erysipelothrix rhusiopathiae.

Authors:  S Makino; K Yamamoto; S Murakami; T Shirahata; K Uemura; T Sawada; H Wakamoto; H Morita; Y Morita
Journal:  Microb Pathog       Date:  1998-08       Impact factor: 3.738

4.  Development of a highly specific recombinant Toxocara canis second-stage larva excretory-secretory antigen for immunodiagnosis of human toxocariasis.

Authors:  H Yamasaki; K Araki; P K Lim; N Zasmy; J W Mak; R Taib; T Aoki
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  [Attenuated acriflavin-fast Erysipelothrix insidiosa. Relationship between its capability to cause arthritis in mice and immunogenicity in swine].

Authors:  K Seto; Y Nishimura; M Fujiki; H Azechi; K Suzuki
Journal:  Nihon Juigaku Zasshi       Date:  1971-08

6.  Enzyme-linked immunosorbent assay for serological diagnosis of Chagas' disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides.

Authors:  A W Ferreira; Z R Belem; E A Lemos; S G Reed; A Campos-Neto
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Protective effect of NaOH-extracted Erysipelothrix rhusiopathiae vaccine in pigs.

Authors:  T Kitajima; E Oishi; K Amimoto; S Ui; H Nakamura; N Okada; O Sasaki; H Yasuhara
Journal:  J Vet Med Sci       Date:  1998-01       Impact factor: 1.267

8.  Quantitative diversity of 67 kda protective antigen among serovar 2 strains of Erysipelothrix rhusiopathiae and its implication in protective immune response.

Authors:  T Kitajima; E Oishi; K Amimoto; U Satoshi; H Nakamura; K Oda; S Katayama; A Izumida; Y Shimizu
Journal:  J Vet Med Sci       Date:  2000-10       Impact factor: 1.267

9.  West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

Authors:  B S Davis; G J Chang; B Cropp; J T Roehrig; D A Martin; C J Mitchell; R Bowen; M L Bunning
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Quality control of inactivated erysipelas vaccines: results of an international collaborative study to establish a new regulatory test.

Authors:  U Rosskopf-Streicher; S Johannes; M Wilhelm; K Cussler
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

View more
  3 in total

1.  Characterization of Erysipelothrix species isolates from clinically affected pigs, environmental samples, and vaccine strains from six recent swine erysipelas outbreaks in the United States.

Authors:  J S Bender; H G Shen; C K Irwin; K J Schwartz; T Opriessnig
Journal:  Clin Vaccine Immunol       Date:  2010-08-18

Review 2.  Erysipelothrix Spp.: Past, Present, and Future Directions in Vaccine Research.

Authors:  Tanja Opriessnig; Taya Forde; Yoshihiro Shimoji
Journal:  Front Vet Sci       Date:  2020-04-15

3.  Use of the rSpaA415 antigen indicates low rates of Erysipelothrix rhusiopathiae infection in farmed cattle from the United States of America and Great Britain.

Authors:  Ana I Cubas Atienzar; Priscilla F Gerber; Tanja Opriessnig
Journal:  BMC Vet Res       Date:  2019-11-01       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.